Wednesday, April 06, 2022 4:09:35 PM
We both have made that point here several times. The buyback had no teeth from day one. Even if they had started buying 150,000,000 shares the minute they announced it, those shares alone wouldn't have gotten us much past .002, if that.
It had no teeth.
The outcry over why it never happened is not equal to how little an impact it potentially had on SP appreciation, imo. Not only that, but they had no obligation to tell us anything about it, because they gave themselves 2 years to get it done. Then Covid, etc, etc.
Things change. Just like the Sp isn't going to stay at .0016 in 2022. :)
Now, they said they would honor prior commitments....not sure if they mean the buyback or not...but if they did, now would be a good time for them to take some, imo. Not holding my breath, as they probably need whatever they have for the acquisition, etc, as they stated...imo.
respects. hl shmn
It had no teeth.
The outcry over why it never happened is not equal to how little an impact it potentially had on SP appreciation, imo. Not only that, but they had no obligation to tell us anything about it, because they gave themselves 2 years to get it done. Then Covid, etc, etc.
Things change. Just like the Sp isn't going to stay at .0016 in 2022. :)
Now, they said they would honor prior commitments....not sure if they mean the buyback or not...but if they did, now would be a good time for them to take some, imo. Not holding my breath, as they probably need whatever they have for the acquisition, etc, as they stated...imo.
respects. hl shmn
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
